Guardian Pharmacy Services (GRDN) amended its long standing loan and security agreement, extending its revolving loan maturity to May 2030 and updating covenants in ways that may matter for investors assessing balance sheet flexibility.

Those revised loan terms arrive while momentum in the stock has been firm, with a 30 day share price return of 12.16% and a year to date share price return of 37.08%, alongside a 1 year total shareholder return of 99.11% at a latest share price of $40.48.

If you are weighing Guardian Pharmacy Services against other healthcare related opportunities, this could be a good moment to see what else is moving through our 39 healthcare AI stocks

With Guardian Pharmacy Services trading at $40.48 and sitting only modestly below analyst and intrinsic estimates, the key question is whether the recent run leaves meaningful upside on the table or whether the stock already reflects its future growth potential.

Most Popular Narrative: 19.1% Overvalued

Guardian Pharmacy Services closed at $40.48, compared with a widely followed narrative fair value of $34, which points to a premium that investors should understand before taking a view.

Active but disciplined M&A, supported by a debt free balance sheet, strong cash conversion above 60% and a flexible shelf registration, positions Guardian to accelerate regional density and national scale, driving incremental revenue and operating leverage.

Want to see what kind of revenue mix, margin lift and earnings trajectory have to line up to support that $34 figure and beyond? The full narrative sets out a detailed playbook for M&A, maturing locations and payer contracts, and it hinges on a few tight assumptions that could meaningfully change the implied upside.

Result: Fair Value of $34 (OVERVALUED)

However, you also need to watch for Medicare Part D and Inflation Reduction Act changes, along with any prolonged slowdown in assisted living admissions that could undermine those growth assumptions.

Another View: Cash Flows Tell A Different Story

While the popular narrative pegs Guardian Pharmacy Services at a fair value of $34, our DCF model points to a value of $42.87 per share, with the current $40.48 price sitting below that estimate. If earnings and cash flows stay on track, is sentiment playing catch up?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Guardian Pharmacy Services for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 48 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If the mixed signals in this article leave you undecided, this is the moment to review the full picture and make a prompt decision for yourself with 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If you stop with one stock, you could miss opportunities that fit your style far better, so widen your watchlist now using the Simply Wall Street Screener.

• Target steady compounding by scanning for companies with strong cash generation and attractive valuations through the 48 high quality undervalued stocks.
• Prioritise resilience by spotting companies with robust financial positions using the solid balance sheet and fundamentals stocks screener (46 results).
• Get ahead of the crowd by searching for under followed companies with strong fundamentals via the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.